Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Provided By PR Newswire
Last update: May 13, 2025
Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026
Read more at prnewswire.com6.63
-0.38 (-5.42%)
Find more stocks in the Stock Screener
KYTX Latest News and Analysis
